Divergent humoral responses to 23-valent pneumococcal polysaccharide vaccine in critically-ill burn and neurosurgical patients

PloS One
Scott W MuellerE N Janoff

Abstract

Critically ill hospitalized patients are at increased risk of infection so we assessed the immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPSV23) administered within six days of injury. This prospective observational study compared the immunogenicity of PPSV23 among critically ill burn and neurosurgical patients at a tertiary, academic medical center. Patients received PPSV23 vaccination within six days of ICU admission per standard of care. Consent was obtained to measure concentrations of vaccine-specific IgG to 14 of 23 serotype capsule-specific IgG in serum prior to and 14-35 days following PPSV23. A successful immunologic response was defined as both a ≥2-fold rise in capsule-specific IgG from baseline and concentrations of >1 mcg/mL to 10 of 14 measured vaccine serotypes. Immunologic response was compared between burn and neurosurgical patients. Multiple variable regression methods were used to explore associations of clinical and laboratory parameters to immunologic responses. Among the 16 burn and 27 neurosurgical patients enrolled, 87.5% and 40.7% generated a successful response to the vaccine, respectively (p = 0.004). Both median post-PPSV23 IgG concentrations (7.79 [4.56-18.1] versus 2.93 [1.49-8.0...Continue Reading

References

Jan 1, 1996·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D M MusherR E Baughn
Jul 11, 2000·Archives of Internal Medicine·P J CarsonE N Janoff
Apr 10, 2002·American Journal of Clinical Pathology·Jerry W PickeringHarry R Hill
Oct 11, 2007·Journal of Burn Care & Research : Official Publication of the American Burn Association·Chris B MooreBruce A Cairns
Oct 28, 2008·The Journal of Allergy and Clinical Immunology·Nathaniel D HareZuhair K Ballas
Oct 29, 2008·Clinics in Chest Medicine·Nicholas S WardAlfred Ayala
Mar 10, 2009·Burns : Journal of the International Society for Burn Injuries·N D'ArpaF Conte
Sep 22, 2009·Burns : Journal of the International Society for Burn Injuries·Jessie S GlasserClinton K Murray
Nov 20, 2009·Clinical and Vaccine Immunology : CVI·Jerry W PickeringHarry R Hill
Mar 12, 2010·BMC Infectious Diseases·Hyunju LeeKyung-Hyo Kim
Jan 14, 2011·Clinical and Vaccine Immunology : CVI·Jose A SerpaMaria C Rodriguez-Barradas
Oct 8, 2011·Journal of Burn Care & Research : Official Publication of the American Burn Association·Christopher S DavisElizabeth J Kovacs
Nov 23, 2011·Burns : Journal of the International Society for Burn Injuries·James E MaceMartin G Schwacha
Dec 22, 2011·JAMA : the Journal of the American Medical Association·Jonathan S BoomerRichard S Hotchkiss
Jun 26, 2012·Immunological Reviews·Peder S OlofssonKevin J Tracey
Oct 3, 2012·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Heleen BorgersXavier Bossuyt
Nov 22, 2012·Nature Reviews. Endocrinology·Valentin A Pavlov, Kevin J Tracey
Dec 4, 2012·Intensive & Critical Care Nursing : the Official Journal of the British Association of Critical Care Nurses·Geoffrey C WallSarah M Yeager
Feb 23, 2013·The Lancet Infectious Diseases·Richard S HotchkissDidier Payen
May 10, 2013·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Joon Young SongMoon H Nahm
May 17, 2013·Clinical and Vaccine Immunology : CVI·Xiaochun ZhangThomas M Daly
May 24, 2013·Clinical and Vaccine Immunology : CVI·Harry R Hill, Jerry W Pickering
Dec 4, 2013·JAMA Neurology·Gabriel CourtiesMatthias Nahrendorf
Dec 18, 2013·Critical Care Medicine·Hector R WongKeith R Walley
Feb 25, 2014·Critical Care Medicine·Callie M ThompsonGrant E O'Keefe
Sep 5, 2014·Clinical and Vaccine Immunology : CVI·D C OlthofJ C Goslings
Dec 19, 2014·Clinical and Vaccine Immunology : CVI·Thomas M Daly, Harry R Hill
Jan 16, 2015·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Arthur LieszRoland Veltkamp
May 11, 2015·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Magdalena M Przybycien-Szymanska, William W Ashley
Sep 16, 2015·The Journal of Allergy and Clinical Immunology·Francisco A BonillaJames W Verbsky
Mar 16, 2016·JAMA : the Journal of the American Medical Association·Lonneke A van VughtUNKNOWN MARS Consortium
Sep 10, 2016·Clinical Neurology and Neurosurgery·J H Tapia-PérezT Schneider

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Brain Injury & Trauma

brain injury after impact to the head is due to both immediate mechanical effects and delayed responses of neural tissues.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.